|
|
|
Corporate Profile: Delcath Systems
| Summary: |
Delcath Systems is focused on the development and commercialization of a cancer therapy that allows isolation and administration high doses of chemotherapeutic agents to a diseased organ or a region of the body to increase efficacy and decrease side effects.
|
| Address (HQ): |
810 Seventh Avenue
Suite 3505
New York, NY 10019 |
| Phone
#'s (HQ): |
| Main |
(212) 489-2100 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Fax
#'s (HQ): |
| Main |
(212) 489-2102 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| email: |
| Main |
info@delcath.com |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Financial
information: |
| DCTH |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
